{"trials":[{"id":3686,"nct_id":"NCT07610135","title":"PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07610135","tracker_url":"publication.php?id=3686","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-10-30","primary_completion_date":"2028-06","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Mood (Psychological Function)","Well Being","Mood","Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"},{"name":"Inactive Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3542,"nct_id":"NCT05866471","title":"Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05866471","tracker_url":"publication.php?id=3542","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-29","start_date":"2025-01-27","primary_completion_date":"2027-11","completion_date":"2028-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":108,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy","Psychedelic Experiences","Vagus Nerve Stimulation"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Transcutaneous auricular Vagus Nerve Stimulation (taVNS)","type":"DEVICE"},{"name":"Psychosocial Support Alone","type":"BEHAVIORAL"},{"name":"Sham taVNS","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3707,"nct_id":"NCT05301608","title":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05301608","tracker_url":"publication.php?id=3707","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2022-03-03","primary_completion_date":"2026-12-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3595,"nct_id":"NCT06884514","title":"Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06884514","tracker_url":"publication.php?id=3595","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2026-06-25","start_date":"2025-04-03","primary_completion_date":"2026-05-13","completion_date":"2026-05-28","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"3,4-Methylenedioxymethamphetamine","type":"DRUG"},{"name":"Psilocybin placebo","type":"DRUG"},{"name":"3,4-Methylenedioxymethamphetamine placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3589,"nct_id":"NCT07079852","title":"The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function","sponsor":"Manoj Doss","registry_url":"https://clinicaltrials.gov/study/NCT07079852","tracker_url":"publication.php?id=3589","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-15","start_date":"2026-09","primary_completion_date":"2028-08","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":48,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin 15mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bfd791b360bb10aa29e67bf9e59fc1b2f04b81de0d1e71a0170094e14bdf29df","facility":"The University of Texas at Austin Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306}],"countries":["United States"]},{"id":3670,"nct_id":"NCT06180759","title":"Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06180759","tracker_url":"publication.php?id=3670","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-01","last_update_date":"2026-04-02","start_date":"2025-01-23","primary_completion_date":"2025-09-29","completion_date":"2025-11-06","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":17,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Intravenous infusion of DMT","type":"DRUG"},{"name":"Intravenous infusion of ketamine","type":"DRUG"},{"name":"Intravenous infusion of placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"Basel","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3698,"nct_id":"NCT06815653","title":"Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.","sponsor":"University College, London","registry_url":"https://clinicaltrials.gov/study/NCT06815653","tracker_url":"publication.php?id=3698","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-02","last_update_date":"2025-11-26","start_date":"2025-03-01","primary_completion_date":"2026-03","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"SINGLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3665,"nct_id":"NCT06081179","title":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT06081179","tracker_url":"publication.php?id=3665","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-11","last_update_date":"2025-11-19","start_date":"2023-10-24","primary_completion_date":"2025-09-22","completion_date":"2025-09-22","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":122,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"3,4 Methylenedioxymethamphetamine","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3617,"nct_id":"NCT05317689","title":"Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults","sponsor":"University of California, San Francisco","registry_url":"https://clinicaltrials.gov/study/NCT05317689","tracker_url":"publication.php?id=3617","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2024-09","last_update_date":"2025-06-10","start_date":"2022-05-26","primary_completion_date":"2025-01-16","completion_date":"2025-07","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocin","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Sublingual Psilocin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3708,"nct_id":"NCT06796361","title":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06796361","tracker_url":"publication.php?id=3708","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-05","last_update_date":"2025-05-28","start_date":"2025-04-21","primary_completion_date":"2026-08","completion_date":"2026-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Ketanserin 40mg plus Psilocybin 40mg","type":"DRUG"},{"name":"40mg Psilocybin","type":"DRUG"},{"name":"20mg Psilocybin","type":"DRUG"},{"name":"10mg Psilocybin","type":"DRUG"},{"name":"5mg Psilocybin","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"ebda5e93566d65c5a0d08874906c8e63c9d620a77b25a4867b0465a3d920d8ef","facility":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3427,"nct_id":"NCT05592379","title":"Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05592379","tracker_url":"publication.php?id=3427","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2025-05-16","start_date":"2023-11-07","primary_completion_date":"2025-02-19","completion_date":"2025-02-19","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":6,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"BASIC_SCIENCE","masking":"SINGLE"},"conditions":["Healthy","Psychedelic Experiences","Sleep"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Clonidine","type":"DRUG"},{"name":"Saline","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"dfd44dbf58c7269a3dc9de0e69126ca81c5af72da9ff806f80dc2a90ae2be7f0","facility":"University of Wisconsin Hospital and Clinics","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3646,"nct_id":"NCT05695495","title":"Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05695495","tracker_url":"publication.php?id=3646","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-04","last_update_date":"2025-04-11","start_date":"2024-06-12","primary_completion_date":"2025-02-02","completion_date":"2025-03-04","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":36,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"N,N-Dimethyltryptamine (5mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (10mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (15mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (20mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (25mg)","type":"DRUG"},{"name":"Placebo (saline)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3586,"nct_id":"NCT06899334","title":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06899334","tracker_url":"publication.php?id=3586","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-03-27","start_date":"2025-04-01","primary_completion_date":"2026-08-01","completion_date":"2026-08-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"DMT","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ac63a9b87b0d17c174df6cd33e9b23cdf05c23cc85c8cd317f6c08206a61f3ac","facility":"University Hospital","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3666,"nct_id":"NCT05523401","title":"Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05523401","tracker_url":"publication.php?id=3666","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-02","last_update_date":"2025-03-05","start_date":"2023-08-16","primary_completion_date":"2024-10-20","completion_date":"2024-11-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"4-bromo-2,5-dimethoxyphenethylamine (10 mg)","type":"DRUG"},{"name":"4-bromo-2,5-dimethoxyphenethylamine (20 mg)","type":"DRUG"},{"name":"4-bromo-2,5-dimethoxyphenethylamine (30 mg)","type":"DRUG"},{"name":"3,4-methylenedioxymethamphetamine","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3545,"nct_id":"NCT02243813","title":"Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02243813","tracker_url":"publication.php?id=3545","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-06","last_update_date":"2024-06-18","start_date":"2015-03","primary_completion_date":"2024-05-31","completion_date":"2024-05-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6732f25d9e7c5ee9eed300cdd40165c9c1b7f0ca5cc99960985a65e7da08f98b","facility":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3564,"nct_id":"NCT05384678","title":"Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05384678","tracker_url":"publication.php?id=3564","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-04","last_update_date":"2024-04-25","start_date":"2022-11-15","primary_completion_date":"2024-03-08","completion_date":"2024-03-13","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"N,N-Dimethyltryptamine (54 mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (108 mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (162 mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (216 mg)","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (108 mg) + dose titration","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"233b6ae11780c805724450c320e419d5b4e212f235659d5a9581ded7c6d5ea19","facility":"Universtity Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3706,"nct_id":"NCT04227756","title":"Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT04227756","tracker_url":"publication.php?id=3706","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-01","last_update_date":"2024-01-24","start_date":"2020-05-19","primary_completion_date":"2022-09-02","completion_date":"2022-09-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":32,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Mescaline","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3634,"nct_id":"NCT05467761","title":"A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05467761","tracker_url":"publication.php?id=3634","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-05","last_update_date":"2023-05-15","start_date":"2023-06","primary_completion_date":"2024-03","completion_date":"2024-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Oral Psilocybin","type":"DRUG"},{"name":"IV Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3468,"nct_id":"NCT04849013","title":"Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT04849013","tracker_url":"publication.php?id=3468","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-03","last_update_date":"2023-03-29","start_date":"2021-08-11","primary_completion_date":"2023-03-27","completion_date":"2023-03-27","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Mescaline 100mg","type":"DRUG"},{"name":"Mescaline 200mg","type":"DRUG"},{"name":"Mescaline 400mg","type":"DRUG"},{"name":"Mescaline 800mg","type":"DRUG"},{"name":"Mescaline 800mg + Ketanserin 40mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3441,"nct_id":"NCT03604744","title":"Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT03604744","tracker_url":"publication.php?id=3441","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-04","last_update_date":"2021-04-27","start_date":"2019-03-27","primary_completion_date":"2021-04-10","completion_date":"2021-04-15","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":28,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3491,"nct_id":"NCT03912974","title":"Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT03912974","tracker_url":"publication.php?id=3491","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-11","last_update_date":"2020-12-01","start_date":"2019-07-04","primary_completion_date":"2020-11-26","completion_date":"2020-11-26","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":27,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Escitalopram","type":"DRUG"},{"name":"Placebo oral capsule","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3448,"nct_id":"NCT03736980","title":"Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT03736980","tracker_url":"publication.php?id=3448","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-11","last_update_date":"2020-11-04","start_date":"2013-10-01","primary_completion_date":"2018-12-31","completion_date":"2018-12-31","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":140,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybine","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3451,"nct_id":"NCT02163707","title":"Pharmacokinetics of Psilocybin in Normal Adult Volunteers","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT02163707","tracker_url":"publication.php?id=3451","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-04","last_update_date":"2020-04-15","start_date":"2014-06","primary_completion_date":"2015-12","completion_date":"2015-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6aef8b3e098d088faf66b099ff25db39f20cd48e8cf64e636833f68681dcc663","facility":"University of Wisconsin, School of Pharmacy","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3579,"nct_id":"NCT02145091","title":"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02145091","tracker_url":"publication.php?id=3579","status":"COMPLETED","status_label":"Completed","status_verified_date":"2019-12","last_update_date":"2019-12-30","start_date":"2014-05","primary_completion_date":"2019-12-26","completion_date":"2019-12-26","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Moderately-high dose of psilocybin","type":"DRUG"},{"name":"Moderately-low dose of psilocybin","type":"DRUG"},{"name":"Very-low dose of psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3504,"nct_id":"NCT02971605","title":"Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02971605","tracker_url":"publication.php?id=3504","status":"COMPLETED","status_label":"Completed","status_verified_date":"2019-08","last_update_date":"2019-09-10","start_date":"2017-07-01","primary_completion_date":"2018-08-21","completion_date":"2018-08-21","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":13,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3628,"nct_id":"NCT00802282","title":"Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT00802282","tracker_url":"publication.php?id=3628","status":"COMPLETED","status_label":"Completed","status_verified_date":"2016-02","last_update_date":"2016-02-24","start_date":"2009-08","primary_completion_date":"2014-02","completion_date":"2014-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":75,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"psilocybin","type":"DRUG"},{"name":"Intensity of support for spiritual practice","type":"BEHAVIORAL"},{"name":"Number of sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2009":1,"2013":1,"2014":2,"2015":1,"2017":1,"2019":2,"2020":1,"2021":1,"2022":3,"2023":4,"2024":1,"2025":6,"2026":2},"statuses":{"Completed":17,"Recruiting":6,"Not yet recruiting":1,"Active, not recruiting":1,"Withdrawn":1},"conditions":{"Healthy":26,"Psychedelic Experiences":2,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Vagus Nerve Stimulation":1,"Sleep":1},"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"bfd791b360bb10aa29e67bf9e59fc1b2f04b81de0d1e71a0170094e14bdf29df","facility":"The University of Texas at Austin Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"ebda5e93566d65c5a0d08874906c8e63c9d620a77b25a4867b0465a3d920d8ef","facility":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"dfd44dbf58c7269a3dc9de0e69126ca81c5af72da9ff806f80dc2a90ae2be7f0","facility":"University of Wisconsin Hospital and Clinics","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"ac63a9b87b0d17c174df6cd33e9b23cdf05c23cc85c8cd317f6c08206a61f3ac","facility":"University Hospital","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"6732f25d9e7c5ee9eed300cdd40165c9c1b7f0ca5cc99960985a65e7da08f98b","facility":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"233b6ae11780c805724450c320e419d5b4e212f235659d5a9581ded7c6d5ea19","facility":"Universtity Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"6aef8b3e098d088faf66b099ff25db39f20cd48e8cf64e636833f68681dcc663","facility":"University of Wisconsin, School of Pharmacy","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"enrollment":{"sum":966,"known_trials":26},"registry_checked_at_utc":"2026-10-09 01:24:43"}